EGFR and non-small cell lung carcinoma: Intriguingly, another phase III trial confirming the effect of osimertinib in untreated NSCLC patients with an activated EGFR mutation (FLAURA trial) showed superiority of osimertinib over gefitinib or erlotinib regarding PFS (HR, 0.46; 95% CI, 0.37 to 0.57; p <0.001; 18.9 vs. 10.2 months, respectively) [31].